Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Urine test could replace repeated scans for adrenal tumors

NCT ID NCT02324647

Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 807 adults with adrenal tumors found by accident during scans for other reasons. Researchers compared the usual approach of repeat CT scans to a single urine steroid profile test to see which is more cost-effective for detecting cancer. The goal is to find a simpler, cheaper way to manage these common tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simpler, more cost-effective way to diagnose adrenal tumors, reducing unnecessary scans.
What could go wrong
This is an observational study, not a treatment trial. The results may not change current practice if the new test is not accurate enough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

807 people

The number who actually took part.

Started

Jan 2015

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The research population consists of adult patients with a recently discovered adrenal incidentaloma who meet the selection criteria of SERENDIPITY. A total number of 1000 patients will be included. These subjects will be recruited from the group of patients in whom CT/MRI-scanning has been performed with visualization of the adrenal glands (i.e. CT/MRI scans of abdomen and/or chest, as the latter often include imaging of the upper abdominal region).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * discrete adrenal mass \> 1 cm in diameter incidentally discovered during CT/MRI-scanning, performed for reasons other than an evaluation for adrenal disease * detection CT/MRI-scan performed ≤ 4 months ago * age 18 years or older. Exclusion Criteria: * extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal cell carcinoma) * radiologic diagnosis of simple cyst or bilateral adrenal masses * allergy to radiocontrast * renal insufficiency (i.e. eGFR \< 30 ml/min/1.73m2) * pregnancy * adrenal incidentaloma visible on previous (i.e. \> 4 months ago) CT/MRI-scan * inability to understand written Dutch.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal incidentaloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex adenoma adrenal cortex carcinoma Adrenal incidentaloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal incidentaloma Adrenocortical carcinoma

Contacts and locations

Locations

  • University Medical Center Groningen

    Groningen, Provincie Groningen, 9700 RB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.